https://www.selleckchem.com/products/AT7519.html
Eltrombopag is the first oral, small-molecule, non-peptide thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. This study investigated the pharmacokinetics of eltrombopag in healthy Chinese subjects and evaluated the effect of **** and genetic polymorphisms on its variability. Forty-eight healthy subjects were administered a single dose of eltrombopag (25mg). Plasma concentrations of eltrombopag were determined using a validated liquid chromatography-tandem mass spectrometry method, and platelet count
Mi piace
Commento
Condividi
